Skip to content

Development of PHY606 as Adjunct Therapy for Anemia Patients

Development of PHY606 as Adjunct Therapy for Anemia Patients

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04974073
Enrollment
39
Registered
2021-07-23
Start date
2017-08-22
Completion date
2019-11-18
Last updated
2021-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Herbal Interaction

Keywords

Anemia, Danggui Buxue Tang, PHY606, Side effects, TCM

Brief summary

Many reasons can cause anemia, decreased RBC production or increased destruction of circulation RBC. The investigators investigate the Danggui Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of genomic and metabolomics in the healthy people and the patiens with anemia.

Detailed description

Many reasons can cause anemia, decreased RBC production or increased destruction of circulating RBC. The reasons of the former are lake of nutrients, bone marrow disorder, low level tropic hormone, inflammation associated with infectious, inflammatory, or malignant disorders and the latter are intravascular hemolysis or blood loss. Anemia is characterized by the sign of pallor (reduced oxyhemoglobin in skin or mucous membranes), fatigue, lightheadedness, and weakness associated with low hemoglobin. Iron deficiency anemia (IDA) is mainly resulted from inadequate iron uptake of food, malabsorption of iron and blood loss. Adult female are easy to have IDA compared to male because of menstruation, pregnancy, lactation and low caloric uptake leading to iron deficiency. In Taiwan, cancer-related and chronic kidney disease also lead to insufficient secretion of erythropoietin (EPO). The cost of long-term use EPO and its derivative drugs is high. Besides, drug resistance, risk of tumor growth and cardiovascular disease are all important issues. However, ferrotherapy will induce GI upset, muscle pain and skin hives. Also, iron supplementation can lead to an increase in infectious disease morbidity in areas where bacterial infections or where malaria are common. Based on the concept of dietetic invigoration, the investigators investigate the Danggui Buxue Tang (PHY606) composed of Angelicae Sinensis Radix and Astragali Radix in the fields of genomics and metabolomics in the healthy people and the patients with anemia. In the meantime, the investigators will explore whether PHY606 activates the immune function, improves anemia and reduces the side effects induced by anemia treatment. Furthermore, the novel metabolites from Angelicae Sinensis Radix and Astragali Radix will be tested from clinic back to the bench including immunological potentiation and hematopoietic function. According to the TCM theory, the investigators integrate with modern medicine and molecular biotechnology to investigate anemia and hope to provide the evidence base for clinical application.

Interventions

DRUGPHY606

Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism

Sponsors

Sheng-Teng Huang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* female: Hb\<11 g/dL; male: Hb\<13.5 g/dL * has no allergic reaction to TCM

Exclusion criteria

* below 20 years old * ever drug abuse or still in drug abuse * pregnant or in breast-feeding women * with psychotic disorders * cardiac arrhythmia with pacemaker * dyscoagulation or thrombocytopenia (platelet\< 15000/uL) or liver dysfunction (\> 2 fold normal range) * with severe disease (cardiac arrest, heart failure, COPD, GI bleeding, etc.) * under another clinical trials

Design outcomes

Primary

MeasureTime frameDescription
Constitution in Chinese Medicine Questionnaire (CCMQ)Change from baseline CCMQ at Day0, Day31, Day93 and Day180.
Serum CytokinesChange from baseline serum cytokines at Day0, Day31 and Day93.Collect blood and measure the level of serum cytokines.

Secondary

MeasureTime frameDescription
GenotypeChange from baseline genotype at Day 0, Day 31 and Day93.Collect blood and analyze the genotype by microarray assay.
Tongue diagnosisChange from baseline tongue diagnosis at Day0 and Day93.Use tongue photos for analysis
Pulse diagnosisChange from baseline Pulse diagnosis at Day0 and Day93.Use the pulse detector to detect the rhythm data of the subject's left and right hand pulse.
Anemia blood testChange from baseline anemia blood at Day 0, Day 31 and Day93.Collect blood and measure the level of ferritin(ng/mL), TIBC(ug/dL), transferrin(mg/dL).

Other

MeasureTime frameDescription
Red Blood Cells (RBC)Change from baseline RBC at Day 0, Day 31 and Day93.Collect blood and measure the value of RBC (x 10\^6/ul).
Hemoglobin (Hb)Change from baseline Hemoglobin at Day 0, Day 31 and Day93.Collect blood and measure the value of Hemoglobin (gm/dL).
Hematocrit (Hct)Change from baseline Hematocrit at Day 0, Day 31 and Day93.Collect blood and measure the value of Hematocrit (%).
Red blood cell volume distribution width (RDW)Change from baseline RDW at Day 0, Day 31 and Day93.Collect blood and measure the value of RDW (%).
PlateletChange from baseline Platelet at Day 0, Day 31 and Day93.Collect blood and measure the value of Platelet (x 10\^3/ul).
Mean corpuscular volume (MCV)Change from baseline MCV at Day 0, Day 31 and Day93.Collect blood and measure the value of MCV (fl).
Mean corpuscular hemoglobin (MCH)Change from baseline MCH at Day 0, Day 31 and Day93.Collect blood and measure the value of MCH (pg).
Mean corpuscular hemoglobin concentration (MCHC)Change from baseline MCHC at Day 0, Day 31 and Day93.Collect blood and measure the value of MCHC (g/dL).
Mean platelet volume (MPV)Change from baseline MPV at Day 0, Day 31 and Day93.Collect blood and measure the value of MPV (fl).
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)Change from baseline FACIT-F score at Day0, Day31, Day93 and Day180.
Pittsburgh Sleep Quality Index (PSQI)Change from baseline PSQI score at Day0, Day31, Day93 and Day180.
36-Item Short Form Health Survey (SF-36)Change from baseline SF-36 score at Day0, Day31, Day93 and Day180.
White blood cell (WBC)Change from baseline WBC at Day 0, Day 31 and Day93.Collect blood and measure the value of WBC (x 10\^3/ul).

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026